BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Any company seriously looking at buying BPAX must factor in that Libigel will get approved. Simes stated that he wanted to bring Libigel across the finish line to maximize the value of the product before selling the rights to the product. That is why so much money has been spent on the safety trials. Coincidentally the consensus is that there is a 90% chance of meeting or exceeding the safety targets. The company has funding to last through next year. If a company waits until after the safety results are released the price will definitely go up.

In order for the company to seriously entertain a buyout it should be in the $1 billion range. $9 - $10 per share. They have to make it appealing to sell early. Remember, back in November 2011 many analysts had a 1 yr target of $6 on BPAX and a strong buy. Libigel has always been about safety first. Even if the sexual satisfaction is in doubt. The testosterone deficiency is real and there is no other approved product on the market for women. Libigel was more then successful in delivering testosterone to pre-menopausal levels while the placebo did not move the needle. The cardiovascular and possible cognitive benefits can only enhance it's value.

In addition

The buying company will obtain:

Global distribution rights to Elestrin outside the US.

Global distribution right to Bio-t-gel outside the US

The future potential winfall from the Pill Plus

Biolook

And all the cancer vaccines. which could be advanced at a quicker rate with proper funding.

With BPAX's deep pipeline a company with deep pockets should see the return on their investment rather quickly.